Karyopharm Therapeutics Inc. cash flow to debt ratio of -32.26% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Karyopharm Therapeutics Inc.'s free cash flow has increased -40.95% from $-127.63M last year to $-75.37M, signaling increasing performance

Karyopharm Therapeutics Inc.'s debt to equity ratio is -0.87, signaling that the company spent its equity and risk bankruptcy.

Karyopharm Therapeutics Inc.'s debt to equity ratio is -0.87, signaling that the company spent its equity and risk bankruptcy.

Karyopharm Therapeutics Inc. has negative EBITDA, making leverage ratio unreliable

Karyopharm Therapeutics Inc.'s interest coverage ratio is -1.78, which means that the company struggles to meet interest obligations, signaling financial risk.

Karyopharm Therapeutics Inc.'s profit margin has decreased (145.19%) in the last year from -52.62% to -129.02%, signaling decreasing performance

Karyopharm Therapeutics Inc.'s short-term assets of $103.15M exceed its short-term liabilities of $92.06M

Karyopharm Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Karyopharm Therapeutics Inc.'s return on equity of 73.11%, is higher than 15.00%, indicating good performance

Karyopharm Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Karyopharm Therapeutics Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Karyopharm Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Karyopharm Therapeutics Inc. has negative free cash flow, indicating cash burn

Karyopharm Therapeutics Inc.'s yearly earnings has decreased 156.52% since last year from $-76.42M to $-196.04M, signaling decreasing performance

Karyopharm Therapeutics Inc.'s yearly revenue has increased 0.57% since last year from $145.24M to $146.07M, signaling increasing performance

ROIC -177.79% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Karyopharm Therapeutics Inc.'s 3-year revenue CAGR of -2.39% is negative, indicating declining revenue over the past 3 years

Karyopharm Therapeutics Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Karyopharm Therapeutics Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Karyopharm Therapeutics Inc. has insufficient data to evaluate this check.

Karyopharm Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Karyopharm Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Karyopharm Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Karyopharm Therapeutics Inc. is overvalued relative to its fair value price of -181.52 based on Earnings Fair Value model

Karyopharm Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Karyopharm Therapeutics Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Karyopharm Therapeutics Inc. has a price-to-sales ratio of 0.29x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue